WO2009126335A3 - Composés inhibiteurs d’ant2 et procédés d’utilisation de ceux-ci - Google Patents

Composés inhibiteurs d’ant2 et procédés d’utilisation de ceux-ci Download PDF

Info

Publication number
WO2009126335A3
WO2009126335A3 PCT/US2009/002295 US2009002295W WO2009126335A3 WO 2009126335 A3 WO2009126335 A3 WO 2009126335A3 US 2009002295 W US2009002295 W US 2009002295W WO 2009126335 A3 WO2009126335 A3 WO 2009126335A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
ant2
inhibitor compounds
diseases
cell proliferation
Prior art date
Application number
PCT/US2009/002295
Other languages
English (en)
Other versions
WO2009126335A2 (fr
Inventor
Naohiro Terada
David A. Ostrov
Original Assignee
University Of Florida Research Foundation, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Florida Research Foundation, Inc. filed Critical University Of Florida Research Foundation, Inc.
Publication of WO2009126335A2 publication Critical patent/WO2009126335A2/fr
Publication of WO2009126335A3 publication Critical patent/WO2009126335A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des procédés de traitement de troubles ou de maladies liés à la prolifération cellulaire, tels que le cancer. Ladite invention porte en outre sur des compositions pharmaceutiques destinées à traiter ces troubles ou ces maladies liés à la prolifération cellulaire.
PCT/US2009/002295 2008-04-08 2009-04-08 Composés inhibiteurs d’ant2 et procédés d’utilisation de ceux-ci WO2009126335A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12352408P 2008-04-08 2008-04-08
US61/123,524 2008-04-08

Publications (2)

Publication Number Publication Date
WO2009126335A2 WO2009126335A2 (fr) 2009-10-15
WO2009126335A3 true WO2009126335A3 (fr) 2010-01-14

Family

ID=41162476

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/002295 WO2009126335A2 (fr) 2008-04-08 2009-04-08 Composés inhibiteurs d’ant2 et procédés d’utilisation de ceux-ci

Country Status (1)

Country Link
WO (1) WO2009126335A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120095263A (ko) * 2011-02-18 2012-08-28 주식회사 바이오인프라 Ａｄｅｎｉｎｅ ｎｕｃｌｅｏｔｉｄｅ ｔｒａｎｓｌｏｃａｔｏｒ ２ ｍＲＮＡ 발현을 감소시켜 유방암을 치료하는 방법
US9795584B2 (en) * 2013-07-30 2017-10-24 University Of South Florida Treating an atypical protein kinase C enzyme abnormality
US9301965B2 (en) * 2014-06-19 2016-04-05 University Of South Florida Method of treating ovarian cancer using a PKC inhibitor
CN112516317B (zh) * 2020-12-10 2021-12-17 暨南大学附属第一医院（广州华侨医院） 一种预防和治疗癌症的药物组合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002088078A2 (fr) * 2001-04-30 2002-11-07 Vertex Pharmaceuticals Incorporated INHIBITEURS DE GSK-3 ET STRUCTURES CRISTALLINES DE LA PROTEINE GSK-3β ET DE COMPLEXES PROTEIQUES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002088078A2 (fr) * 2001-04-30 2002-11-07 Vertex Pharmaceuticals Incorporated INHIBITEURS DE GSK-3 ET STRUCTURES CRISTALLINES DE LA PROTEINE GSK-3β ET DE COMPLEXES PROTEIQUES

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRAS MORGANE LE ET AL.: "Chemosensitization by Knockdown of Adenine Nucleotide Translocase-2", CANCER RES, vol. 66, no. 18, 2006, pages 9143 - 9152 *
CHEVROLLIER ARNAUD ET AL.: "ANT2 Isoform Required for Cancer Cell Glycolysis", JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, vol. 37, no. 5, 2005, pages 307 - 316 *
WELCH KAREN T. ET AL.: "Discovery of non-carbohydrate inhibitors of aminoglycoside modifying enzymes", BIOORGANIC AND MEDICINAL CHEMISTRY, vol. 13, 2005, pages 6252 - 6263 *

Also Published As

Publication number Publication date
WO2009126335A2 (fr) 2009-10-15

Similar Documents

Publication Publication Date Title
WO2013163190A8 (fr) Inhibiteurs d'adn pk
WO2009155001A3 (fr) Inhibiteurs de signalisation de la protéine wnt
WO2010011296A3 (fr) Inhibiteurs de désacétylase et leurs utilisations
WO2010014253A3 (fr) Composés inhibiteurs d’ant4 et leurs procédés d’utilisation
WO2008128072A3 (fr) Inhibiteurs de la kinase axl
WO2009011850A3 (fr) Nouveaux composés thérapeutiques
WO2008079988A3 (fr) Quinazolines destinés à l'inhibition de pdk1
WO2010111406A3 (fr) Composés et leurs utilisations thérapeutiques
WO2006071960A3 (fr) Compositions et procedes de traitement de troubles de la proliferation cellulaire
WO2007123892A3 (fr) Inhibiteurs raf et leurs utilisations
WO2007109279A3 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
IN2012DN03883A (fr)
WO2008124660A3 (fr) Procédés et compositions pour le traitement du cancer
WO2006106326A8 (fr) Heterocycles substitues et leur utilisation en tant qu’inhibiteurs de la chk1, de la pdk1 et de la pak
WO2007095124A3 (fr) Derives, compositions de benzazole et procedes d'utilisation en tant qu'inhibiteurs de la kinase aurora
WO2012024620A3 (fr) Inhibiteurs de l'autotaxine et leurs utilisations
WO2011082273A3 (fr) Composés de pyrroloaminopyrimidine substitués
WO2008131000A3 (fr) Inhibiteurs mcl-1 indole 7-substitués
WO2011032169A3 (fr) Compositions et formulations pharmaceutiques comprenant des inhibiteurs du domaine d'homologie à la pleckstrine et leurs méthodes d'utilisation
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
MX2013001970A (es) Compuestos de pirrolopirimidina y usos de los mismos.
MX2009006535A (es) Derivados de indol-4-il-pirimidinil-2-il-amina y su uso como inhibidores de cinasa dependiente de ciclina.
WO2011082270A3 (fr) Composés imidazopyridinyl-aminopyridine substitués
MY165728A (en) Selective glycosidase inhibitors and uses thereof
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09729617

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09729617

Country of ref document: EP

Kind code of ref document: A2